Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Rosetta Genomics and Rabin Medical Center collaborate to develop microRNA-based diagnostics

Rosetta Genomics : 26 June, 2008  (Company News)
Rosetta Genomics is collaborating with the Rabin Medical Center in Israel to develop microRNA-based diagnostics in the fields of oncology, gynaecology, and obstetrics.
The collaboration will use the potential of microRNAs as highly sensitive and specific biomarkers, to develop a wide range of diagnostic and prognostic tests. The move is the company's first collaboration to include a focus on diagnostics for women's health indications.

'MicroRNAs' unique characteristics as sensitive and specific biomarkers, coupled with our strong development engines, enable us to expand and advance our development programs outside the oncology field,' said Amir Avniel, president and chief executive officer of Rosetta Genomics. 'There is true unmet medical need for better diagnostics in Women's Health, and I am confident that The Rabin Medical Center's world-renowned researchers will assist us in bringing better diagnostics to patients worldwide.'

'As a leading research and clinical centre at the forefront of science, we understand the importance of transforming cutting-edge technologies into next-generation products that will benefit patients worldwide,' said Dr Eyran Halpern, chief executive officer of the Rabin Medical Center. 'MicroRNAs are proving to be highly effective biomarkers for a wide range of indications. I believe that by leveraging the proprietary technologies developed by Rosetta Genomics, this collaboration will be a fruitful one.'

'This collaboration is an important step towards improving women's health,' said professor Moshe Hod, director of the Division of Maternal Fetal Medicine in the Hospital for Women at Rabin Medical Center, and chairman of the Rosetta Genomics Medical Advisory Board. ' There is true unmet need for improved diagnostics for a wide range of indications, and research is repeatedly indicating microRNAs have the potential to be used as effective biomarkers not only in oncology.'

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo